Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rapport Therapeutics (RAPP) EPS (Basic) (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of EPS (Basic) data on record, last reported at -$0.42 in Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 38.24% to -$0.42 in Q1 2026 year-over-year; TTM through Mar 2026 was -$2.59, a 13.67% increase, with the full-year FY2025 number at -$2.86, up 24.34% from a year prior.
  • EPS (Basic) reached -$0.42 in Q1 2026 per RAPP's latest filing, up from -$0.71 in the prior quarter.
  • Over the last five years, EPS (Basic) for RAPP hit a ceiling of -$0.12 in Q4 2024 and a floor of -$11.07 in Q1 2024.
  • A 4-year average of -$2.93 and a median of -$0.73 in 2025 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): skyrocketed 98.57% in 2024, then tumbled 491.67% in 2025.
  • Tracing RAPP's EPS (Basic) over 4 years: stood at -$8.38 in 2023, then soared by 98.57% to -$0.12 in 2024, then crashed by 491.67% to -$0.71 in 2025, then skyrocketed by 40.85% to -$0.42 in 2026.
  • Business Quant data shows EPS (Basic) for RAPP at -$0.42 in Q1 2026, -$0.71 in Q4 2025, and -$0.71 in Q3 2025.